Macrogenics (MGNX) Assets (2012 - 2026)
Macrogenics (MGNX) posted quarterly Assets of $217.9 million for Q1 2026, down 2.98% year-over-year from $224.6 million in Q1 2025, and down 15.17% quarter-over-quarter from $256.8 million in Q4 2025.
Macrogenics (MGNX) Assets (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Assets for 15 consecutive years, with $217.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 2.98% year-over-year to $217.9 million; the TTM figure through Mar 2026 stood at $217.9 million (down 2.98% YoY), while the FY2025 annual figure was $256.8 million, down 1.84% from the prior year.
- Assets slipped to $217.9 million in Q1 2026 per MGNX's latest filing, from $256.8 million in the prior quarter.
- Across five years, Assets topped out at $343.5 million in Q1 2023 and bottomed at $195.3 million in Q3 2022.
- Historically, Assets has averaged $261.4 million across 5 years, with a median of $261.7 million in 2024.
- Annual changes were most pronounced in 2022 — Assets sank 50.19% — and 2023, when it surged 74.03%.
- Macrogenics' Assets stood at $280.5 million in 2022, then climbed by 6.4% to $298.4 million in 2023, then retreated by 12.32% to $261.7 million in 2024, then slipped by 1.84% to $256.8 million in 2025, then decreased by 15.17% to $217.9 million in 2026.
- Business Quant data shows MGNX's Assets at $217.9 million in Q1 2026, $256.8 million in Q4 2025, and $270.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 217.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 217.87 Mn |
| Dec 31, 2025 | 256.85 Mn |
| Sep 30, 2025 | 270.76 Mn |
| Jun 30, 2025 | 245.42 Mn |
| Mar 31, 2025 | 224.57 Mn |
| Dec 31, 2024 | 261.66 Mn |
| Sep 30, 2024 | 264.49 Mn |
| Jun 30, 2024 | 201.14 Mn |
| Mar 31, 2024 | 248.29 Mn |
| Dec 31, 2023 | 298.42 Mn |
| Sep 30, 2023 | 339.97 Mn |
| Jun 30, 2023 | 305.65 Mn |
| Mar 31, 2023 | 343.50 Mn |
| Dec 31, 2022 | 280.47 Mn |
| Sep 30, 2022 | 195.35 Mn |
| Jun 30, 2022 | 218.04 Mn |
| Mar 31, 2022 | 271.45 Mn |
| Dec 31, 2021 | 335.25 Mn |
| Sep 30, 2021 | 392.16 Mn |
| Jun 30, 2021 | 425.91 Mn |